Scilex Holding vs Verrica Pharmaceuticals
Verrica Pharmaceuticals is the larger business, with $35.6m of revenue in fiscal 2025 against $30.3m for Scilex Holding (1.2 times as much). Verrica Pharmaceuticals grew faster (370.2% against -46.5%). Verrica Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -50.3% against -1236.4%.
| Latest fiscal year | Scilex HoldingSCLX, 2025 | Verrica PharmaceuticalsVRCA, 2025 |
|---|---|---|
| Revenue | $30.3m | $35.6m |
| Revenue growth | -46.5% | 370.2% |
| Net income | −$374m | −$17.9m |
| Operating margin | -1143.7% | -34.2% |
| Net margin | -1236.4% | -50.3% |
| Return on equity | — | — |
| Free cash flow | $3.7m | −$17.6m |
| Cash | $5.0m | $30.1m |
| Total debt | $106m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 34 | 76 |
| Market value | $13.4m | $57.5m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 13 sales | 12 buys, 0 sales |